Kimberly J. Payne

University of Manchester — United Kingdom

Medicine · Health Sciences

35h-index3.2kcitations165works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Lymphoblastic Leukemia research(93), Childhood Cancer Survivors' Quality of Life(25), Acute Myeloid Leukemia Research(24), Chronic Lymphocytic Leukemia Research(24), Chronic Myeloid Leukemia Treatments(24)

Publications165 total

ABS0909 COST-EFFECTIVENESS ANALYSIS OF A SYNOVIAL TISSUE BIOPSY TO INFORM SECOND-LINE BIOLOGIC TREATMENT AFTER INADEQUATE RESPONSE TO A TUMOUR NECROSIS FACTOR-ALPHA INHIBITOR FOR RHEUMATOID ARTHRITIS
Annals of the Rheumatic Diseases·2025Open Access
The Value and Challenges of an Ambulatory Intermediate Care Clinic
Journal of Ambulatory Care Management·2025
Reduce unnecessary transfers from clinics to EDs
American Nurse Journal·2023· 1 cited
TSLP as a Potential Therapy in the Treatment of CRLF2 B Cell Acute Lymphoblastic Leukemia
International Journal of Molecular Sciences·2022· 11 citedOpen Access
Abstract 1528: Molecular mechanisms of TSLP as a therapy for CRLF2 B-Cell acute lymphoblastic leukemia
Cancer Research·2022
Platelet and neutrophil responses to <i>Porphyromonas gingivalis</i> in human whole blood
Molecular Oral Microbiology·2021· 10 citedOpen Access
Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia
Leukemia·2021· 22 citedOpen Access
Increased Incidence of IKZF1 deletions and IGH-CRLF2 translocations in B-ALL of Hispanic/Latino children—a novel health disparity
Leukemia·2021· 29 citedOpen Access
A novel vitamin D gene therapy for acute myeloid leukemia
Translational Oncology·2020· 17 citedOpen Access
Abstract 470: High-dose TSLP decreases in vivo tumor burden in preclinical models of CRLF2 B-ALL
Cancer Research·2020
Abstract 2927: Targeted combination treatment for B-cell acute lymphoblastic leukemia
Cancer Research·2020
Discovery of proangiogenic CD44+mesenchymal cancer stem cells in an acute myeloid leukemia patient’s bone marrow
Journal of Hematology & Oncology·2020· 18 citedOpen Access
IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia
Blood·2020· 69 citedOpen Access
Developing a novel biologic for the treatment of high-risk B cell acute lymphoblastic leukemia
The Journal of Immunology·2020
The Current Genomic and Molecular Landscape of Philadelphia-like Acute Lymphoblastic Leukemia
International Journal of Molecular Sciences·2020· 40 citedOpen Access
CK2 Inhibitor CX4945 Shows Strong In Vivo Anti Leukemia Effect in AML Via Augmented Ikaros-Mediated Regulation of Global Epigenetic Landscape
Blood·2019
CK2 Inhibitor CX4945 Shows Strong In Vivo Synergistic Anti-Leukemia Activity with Rapamycin in B-ALL Due to Enhanced Ikaros Mediated Repression of mTOR Pathway
Blood·2019· 1 cited
Belimumab alters transitional B-cell subset proportions in patients with stable systemic lupus erythematosus
Lupus·2019· 9 citedOpen Access
Abstract 286: Synergistic efficacy of CK2 inhibitor with common chemotherapy drugs by restoring Ikaros function in high-risk ALL
Experimental and Molecular Therapeutics·2019· 1 cited
Abstract 4400: Epigenetic regulation of CDC16 expression by the ikaros and casein kinase II (CK2) in T-cell acute lymphoblastic leukemia (T-ALL)
Cancer Research·2019
page 1 of 9Next →

Frequent Co-authors

Sinisa Dovat(21), Chunhua Song(14), Zheng Ge(10), Chandrika Gowda(7), Yali Ding(7), Ruijun Su(7), Gay M. Crooks(6), Ineavely Báez(6), Lora W. Barsky(5), Dhimant Desai(5), Abby J. Weldon(5), Paul W. Kincade(4), Abigail Benitez(4), Amanda Neises(4), Xiao‐Bing Zhang(4), Zafer Gürel(4), Terry‐Ann Milford(4), Feng Yue(4), Jonathon L. Payne(4), Mark E. Reeves(4)